Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|August 18, 2017
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetesRakel F Johansen, Esben Søndergaard, Helle Linnebjerg, et al.Journal of Diabetes|April 17, 2014
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspartWilliam V Tamborlane, Eric Renard, R Paul Wadwa, et al.Diabetes|October 4, 2013
Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolismMary Courtney Moore, Marta S Smith, Vikram P Sinha, et al.Diabetes Care|May 20, 2011
Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemiaItamar Raz, Antonio Ceriello, Peter W Wilson, et al.Diabetes Care|July 13, 2012
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetesRichard M Bergenstal, Julio Rosenstock, Richard F Arakaki, et al.Diabetes Care|March 29, 2002
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centersSamy I McFarlane, Scott J Jacober, Nathaniel Winer, et al.Diabetes Care|November 30, 2012
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover studyJulio Rosenstock, Richard M Bergenstal, Thomas C Blevins, et al.Diabetes, Obesity & Metabolism|August 4, 2016
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trialsHenry Ginsberg, Bertrand Cariou, Trevor Orchard, et al.Diabetes Care|June 28, 2007
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemiaMark A Deeg, John B Buse, Ronald B Goldberg, et al.Diabetes, Obesity & Metabolism|November 27, 2016
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetesNiels Porksen, Helle Linnebjerg, Parag Garhyan, et al.Pageof 3